Takeda Pharmaceutical Company Limited

$ 4 934.00 -2.04 %

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.

CEO: Christophe Weber - https://www.takeda.com

Price objectif

-

Recommandation

Buy

DCF

$ 14 510.65

Loading data...

4502.T vs S&P500

Loading data...

No data available.

Quick ratio

0.70

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

41.30

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

119.48

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

2.61 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

2.59 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.41

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.63

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

500.69

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

162.65 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
1.18 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.24 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.32 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.